Wolverine Trading
RLMD icon

Wolverine Trading’s Relmada Therapeutics RLMD Stock Holding History

Wolverine Trading’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,300
Closed -$25.6K – 4991
2023
Q2 		$25.6K Buy
+10,300
New +$28.5K ﹤0.01% 4074

Other funds holding RLMD

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

Wolverine Trading's RLMD Position: Q2 2024 in Review

Wolverine Trading sold out of Relmada Therapeutics (RLMD) in Q2 2024, closing a stake of 11,511 shares — an estimated $41.6K sold.

Wolverine Trading first reported a position in RLMD in Q4 2023 and held it in 2 quarters. The position peaked at $53.5K in Q1 2024. 79 funds tracked by Wall St. Rank hold RLMD as of Q2 2024.

  • Wolverine Trading reported no remaining Relmada Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Wolverine Trading sold 11,511 Relmada Therapeutics shares in Q2 2024, an estimated $41.6K.
  • Wolverine Trading first reported a position in Relmada Therapeutics in Q4 2023 and held it in 2 quarters.
  • Wolverine Trading's Relmada Therapeutics position peaked at $53.5K in Q1 2024.
  • 79 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2024.

Based on Wolverine Trading's 13F filing for Q2 2024, filed 14 Aug 2024.